KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Assets (2016 - 2026)

TherapeuticsMD filings provide 17 years of Other Non-Current Assets readings, the most recent being $419000.0 for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 98.58% to $419000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $419000.0, a 98.58% increase, with the full-year FY2025 number at $444000.0, up 241.54% from a year prior.
  • Other Non-Current Assets hit $419000.0 in Q1 2026 for TherapeuticsMD, down from $444000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $470000.0 in Q3 2025 to a low of $58000.0 in Q4 2023.
  • Median Other Non-Current Assets over the past 5 years was $253000.0 (2022), compared with a mean of $243764.7.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 99.48% in 2022 and later skyrocketed 710.34% in 2025.
  • TherapeuticsMD's Other Non-Current Assets stood at $253000.0 in 2022, then plummeted by 77.08% to $58000.0 in 2023, then soared by 124.14% to $130000.0 in 2024, then surged by 241.54% to $444000.0 in 2025, then fell by 5.63% to $419000.0 in 2026.
  • The last three reported values for Other Non-Current Assets were $419000.0 (Q1 2026), $444000.0 (Q4 2025), and $470000.0 (Q3 2025) per Business Quant data.